Search

Recent years have witnessed a renaissance in the use of locoregional tumor therapy as part of a multimodal therapeutic approach to a variety of solid tumors, and attempts are underway to define its value in the overall therapeutic strategy for individual tumor entities. This flourishing of interest in locoregional tumor therapy derives from a series of important new developments concerning methodology, drug treatments, and instrumentation. The resulting approaches include not only optimized locoregional chemotherapy and chemoembolization for hepatocellular carcinoma and other tumors, but also other “targeted” therapies such as stereotactic radiosurgery, radiofrequency ablation, intra-arterial administration of radiopharmaceuticals, and complex new methods of chemoembolization of liver metastases involving the use of multiagent chemotherapy in combination with targeted drugs, drug-eluting beads/microspheres, or nanoparticles. In addition, intraperitoneal and intrapleural therapies, e.g., cytoreduction plus hyperthermic intraperitoneal chemotherapy, are now a standard element of the strategy for a range of tumors. It is vital that practitioners have the necessary expertise in the use of these locoregional treatment methods and understand how to combine them optimally with modern systemic therapies. With that goal in mind, this book presents, in condensed form, the clinical results achieved using various locoregional tumor therapies. In so doing, it will allow the reader to rapidly retrieve the information on indications and effectiveness that is required for optimal integration of these highly effective therapies into modern, yet more complex treatment strategies.

Since the introduction of transarterial tumour therapy of the liver at the beginning of the 1970s, its indications have continuously increased. The constant further development of angiography techniques on the one hand and improved understanding of the pathogenesis of tumours on the other have today led to transvascular therapy, such as transarterial chemoembolisation (TACE), becoming one of the most important approaches in the management of liver tumours. After the indication for it has been made on an interdisciplinary basis, the different disciplines, essentially radiology, surgery and internal medicine, can together achieve an optimum treatment outcome for patients.

Primary lung tumors are now a global health problem. The incidence has risen dramatically during the last 5--6 decades, reflecting the popularity of cigarette smoking. In this, the fifth volume dealing with lung cancer in the series KappaCANCER TREATMENT AND RESEARCHkappa, many current research topics are covered by notable authorities, including chemoprevention, growth factors, multidrug resistance, new agents, and haematopoietic growth factors. Altogether, the 17 chapters from twelve countries highlight some of the rapid developments taking place in basic and clinical research of lung cancer. These chapters not only give up-to-date information, they will also stimulate further research into this man-made disease which was almost unheard of a century ago.

This volume presents a detailed survey of imaging, multidetector-row computed t- various methodologies related to diagno- ography, helical computed tomography, sis, therapy, and prognosis of liver cancer, ultrasonography, and power Doppler ult- including colorectal liver metastases and sound, for the prognosis and assessment of biliary tract carcinomas, while the already liver cancer treatment (including HCC) and published Volumes 1, 2, 3, and 4 detail liver metastases from colorectal cancer are similar aspects of breast, lung, prostate, discussed in detail, as is the use of radiof- gastrointestinal, and colorectal cancer, quency ablation in hepatic tumors. respectively. Approximately 50% of colorectal cancer Surgical resection is the standard therapy (CRC) patients develop liver metastases for resectable liver disease, resulting in during the course of their disease, and 5-year overall survival rates of 20–40%. more than 50% of patients who die of CRC One the other hand, the median overall have liver metastases at autopsy. Regional survival of patients with unresectable liver lymph node (RLN) involvement in patients metastases does not exceed 18–20 months, with colorectal liver metastases is one with a 5-year survival rate approaching of the worst prognostic factors. Recent zero. In other words, there is virtually no studies indicate that for these patients, long-term survival. Both resectable and combined liver resection and pedicular unresectable liver cancers are discussed lymphadenectomy can be recommended, in this volume. The method of selecting when RLN metastases respond to p- patients for resection of hepatic colorectal operative chemotherapy.

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever and whenever you need it most!Equips you to select the most appropriate tests and imaging studies for diagnosing and staging each type of cancer, and manage your patients most effectively using all of the latest techniques and approaches. Explores all of the latest scientific discoveries'implications for cancer diagnosis and management. Employs a multidisciplinary approach - with contributions from pathologists, radiation oncologists, medical oncologists, and surgical oncologists - for well-rounded perspectives on the problems you face. Offers a user-friendly layout with a consistent chapter format • summary boxes • a full-color design • and more than 1,445 illustrations (1,200 in full color), to make reference easy and efficient.Offers access to the book's complete contents online – fully searchable – from anyplace with an Internet connection. Presents discussions on cutting-edge new topics including nanotechnology, functional imaging, signal transduction inhibitors, hormone modulators, complications of transplantation, and much more. Includes an expanded color art program that highlights key points, illustrates relevant science and clinical problems, and enhances your understanding of complex concepts.

Top Investigators Explore the Complexities of Angiogenesis Cancer ResearchThe targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev

Title from PDF title page (viewed on Oct. 4, 2007).

Regional cancer therapies remain important options in the management of malignant disease, in spite of the venue of more targeted agents for systemic therapies. New te- nologies and better guidance systems for radiofrequency ablation and intrastitial laser therapies, highly selective intravascular approaches with improved catheters and gu- ance systems, improved agents for embolizations, and new vasoactive drugs for isolated limb and liver perfusions are just a few of the new developments in a field that is alive and progressing. Regional Cancer Therapy, so well put together by the editors Peter M. Schlag and Ulrike S. Stein, presents an overview of today's realities and tomorrow's possibilities. Regional cancer therapy models provide ways to make new discoveries about tumor biology and new agents that may be used regionally as well as systemically. This book should therefore be of interest to all clinicians and scientists with an interest in tumor biology as well as clinical advances. Alexander M. M. Eggermont, MD, PhD Professor and Head of Surgical Oncology Erasmus University MC—Daniel den Hoed Cancer Center Rotterdam, the Netherlands v PREFACE The treatment of malignant tumors has been substantially improved in recent years due to developments in clinical medicine and technology as well as by advances in mole- lar biological research. Modern molecular and genetic techniques allow the charact- ization of molecules that are decisive for tumor development and progression.